We are proud to announce that the U.S. Food and Drug Administration (FDA) has officially cleared Plus Therapeutics’ Investigational New Drug (IND) application for REYOBIQ™, a novel radiotherapeutic under development for the treatment of pediatric patients with difficult-to-treat brain cancers.
The new trial, known as ReSPECT-PBC, will focus on children with:
This marks a significant milestone for Plus Therapeutics as we expand our clinical development into the pediatric neuro-oncology space, where treatment options remain extremely limited and the need for innovation is critical.
The ReSPECT-PBC trial is supported by a $3.0 million research grant from the U.S. Department of Defense, reflecting strong governmental support for advancing new therapies for pediatric brain cancer.
“FDA clearance of this IND allows us to take the next step in evaluating REYOBIQ™ for pediatric patients, building on our existing efforts in adult glioblastoma and leptomeningeal metastases,” said Marc Hedrick, M.D., President & CEO of Plus Therapeutics.
Read the full press release: Plus Therapeutics Announces FDA Clearance for Pediatric Brain Cancer Trial
To stay informed about our full clinical trial portfolio, including RESPECT-PBC and other studies using REYOBIQ™, visit: respect-trials.com
Recent Comments